In Pfizer Business Review, Established Products Unit Is Most "Complex," Simmons Says
This article was originally published in The Pink Sheet Daily
Executive Summary
President of Emerging Markets and Established Products David Simmons offers a glimpse into how Pfizer's strategic business review is progressing.
You may also be interested in...
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.
Reading Into Pfizer's Changes: First Steps For New CEO
Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.